Browse the evidence

SGLT2 inhibitors are preferred over GLP1RAs for adults with type 2 diabetes and heart failure to reduce major adverse cardiovascular events and worsening heart failure, while GLP1RAs are preferred for chronic kidney disease if SGLT2is are not tolerated.

If you have type 2 diabetes and heart failure, ask about SGLT2 inhibitors (like empagliflozin or dapagliflozin), as they are proven to help your heart. If you have kidney disease, SGLT2 inhibitors are also preferred, but if you can't take them, GLP-1 agonists (like dulaglutide) are a good alternative for protecting your kidneys. Your doctor will choose based on your specific organ risks.

Metformin produces moderate weight loss (3-5% reduction) in adults with T2DM or obesity, primarily by lowering hunger and reducing calorie intake, and can prevent weight gain associated with antipsychotic medications.

Metformin is a cornerstone treatment for Type 2 Diabetes that also offers moderate weight loss benefits (typically 3-5% body weight reduction). It works by reducing appetite and calorie intake. It is particularly useful for patients who need to counteract weight gain caused by other medications, such as antipsychotics. While gastrointestinal side effects are common, they often subside, and the long-term weight and metabolic benefits are substantial.

Metabolic surgery (bariatric surgery) provides superior long-term glycemic control, higher T2D remission rates, and greater weight loss compared to intensive lifestyle and medical management alone in patients with Type 2 Diabetes and obesity.

If you have Type 2 Diabetes and obesity, standard diet and medication often fail to provide long-term remission. Metabolic surgery is a highly effective, standard-of-care option that offers significantly better weight loss and diabetes control than lifestyle changes alone, with safety profiles comparable to common surgeries.

Lisdexamfetamine dimesylate is the only FDA-approved medication for Binge Eating Disorder and significantly reduces binge eating days and increases binge cessation rates compared to placebo.

Lisdexamfetamine is the only FDA-approved medication for Binge Eating Disorder. Clinical trials show it significantly reduces binge eating days and increases the likelihood of stopping binges compared to a placebo. However, because it is a stimulant, it requires caution in patients with T2DM who may also have hypertension or cardiovascular issues. Discuss the risks and benefits with your doctor if you are considering medication.

GLP-1 receptor agonists improve glycemic control, promote significant weight loss, and reduce cardiovascular events in patients with type 2 diabetes.

If you have type 2 diabetes and heart risks, GLP-1 injections can help lower blood sugar, lose weight, and protect your heart.

Tirzepatide, a dual GIP and GLP-1 receptor agonist, provides superior glycemic control and greater weight loss compared to GLP-1 receptor agonists.

Tirzepatide is a newer injection that works on two hormones to lower blood sugar and lose more weight than older GLP-1 drugs.

Subcutaneous semaglutide (2.4 mg once weekly) produces clinically significant weight loss (mean -14.9% body weight) compared to placebo when combined with lifestyle interventions.

If you have obesity, adding weekly semaglutide (2.4 mg) to your existing diet and exercise plan can help you lose significantly more weight (around 15%) than diet and exercise alone. Start with the lowest dose and increase it slowly every few weeks to avoid stomach issues.

GLP-1 receptor agonists improve glycemic control and promote weight loss in type 2 diabetes and obesity by stimulating glucose-dependent insulin secretion and reducing appetite, with efficacy superior to many existing therapies.

GLP-1 receptor agonists are highly effective treatments for Type 2 Diabetes and Obesity. They work by mimicking a natural hormone to increase insulin when blood sugar is high and reducing appetite. While they are usually given by injection (some are oral), they offer significant benefits in lowering blood sugar and losing weight, often more so than older diabetes medications. Common side effects like nausea are frequent but often improve over time. These drugs are not suitable for everyone, particularly those with a history of certain thyroid cancers or pancreatitis.

Multi-agonists targeting GLP-1R along with other receptors (GIPR, GCGR) demonstrate superior weight loss and glycemic control compared to single GLP-1R agonists.

Newer 'multi-agonist' diabetes and obesity drugs (like Tirzepatide) target multiple hormone receptors simultaneously. This approach often leads to greater weight loss and better blood sugar control than older single-target GLP-1 drugs. They are taken as weekly injections and are approved for both Type 2 Diabetes and Obesity.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, produces superior glycemic control and greater weight loss compared to selective GLP-1 agonists (semaglutide) and basal insulins (degludec, glargine) in patients with type 2 diabetes.

Tirzepatide is a once-weekly injection that works by mimicking two gut hormones (GIP and GLP-1) to improve how your body handles sugar and fat. Clinical trials show it lowers blood sugar and reduces body weight more effectively than standard diabetes medications like insulin or other GLP-1 drugs like semaglutide. It is prescribed for adults with type 2 diabetes or obesity, starting at a low dose to minimize stomach upset, and increasing over time. It is not suitable for people with a specific family history of thyroid cancer.

Tirzepatide induces significant weight loss (up to 20.4% with 15mg dose) in individuals with overweight or obesity, comparable to effects observed with bariatric surgery.

For individuals with obesity, tirzepatide offers a non-surgical path to significant weight loss. In clinical trials, the highest dose resulted in an average loss of over 20% of body weight, which is comparable to the results typically seen with bariatric surgery. This makes it a powerful alternative for those who cannot undergo or prefer to avoid surgery.

GLP-1 receptor agonists (e.g., semaglutide, liraglutide) produce significant weight loss in adults with obesity, primarily through central appetite suppression and delayed gastric emptying, with efficacy varying by specific agent and dose.

GLP-1 agonists like semaglutide (2.4mg weekly) and liraglutide (1.8mg daily) are highly effective for weight loss, significantly outperforming lifestyle changes alone. They work by slowing digestion and reducing hunger signals in the brain. While effective, they require chronic use to maintain weight loss, and side effects like nausea are common.

Dual incretin agonists (GLP-1/GIP) such as tirzepatide demonstrate superior weight loss efficacy compared to single GLP-1 agonists.

Tirzepatide (15mg weekly) is a dual-acting drug (GLP-1/GIP) that produces greater weight loss (~21%) than single-acting GLP-1 drugs. It is currently approved for type 2 diabetes and under review for obesity. It requires weekly injection and medical supervision.

Once-weekly 2.4 mg semaglutide produces significant weight loss and cardiometabolic improvements in adults with obesity, regardless of whether the treatment is combined with standard or very intensive lifestyle interventions.

Take 2.4 mg of semaglutide once weekly, starting with a low dose (0.25 mg) and increasing every 4 weeks to minimize side effects. While you should still eat healthy and exercise, do not expect lifestyle changes to significantly boost weight loss beyond what the medication provides. The drug itself is the primary driver of weight loss.

GLP-1 receptor agonists (e.g., semaglutide, tirzepatide) induce substantial weight loss (up to 20%) by acting on CNS neural circuits, specifically the dorsal vagal complex.

GLP-1 medications like semaglutide and tirzepatide are highly effective for weight loss, often resulting in 10-20% body weight reduction. They work by acting on brain circuits that control appetite. You must take them chronically, as stopping leads to weight regain. Side effects like nausea are common but manageable.

Metformin (850 mg twice daily) reduces the incidence of type 2 diabetes by 31% compared to placebo in high-risk adults, with greater efficacy in individuals with a BMI >= 35 kg/m2 and fasting glucose 110–125 mg/dL.

If you are at high risk for type 2 diabetes, metformin (850 mg twice daily) can reduce your risk by 31%. However, it is most effective if you have a BMI of 35 or higher or a fasting glucose between 110-125 mg/dL. Lifestyle changes remain more effective overall.

Once-weekly subcutaneous semaglutide at 2.4mg induces significant weight loss (mean 14.9%) in adults with obesity, significantly outperforming placebo.

For adults with obesity, once-weekly subcutaneous semaglutide at 2.4mg is a highly effective treatment for weight loss, averaging a 14.9% reduction in body weight over 68 weeks when combined with lifestyle changes. This is significantly better than placebo. Patients should expect potential gastrointestinal side effects, which are usually temporary, and adhere to the titration schedule to minimize them.

Once-weekly subcutaneous semaglutide at 1.0mg significantly lowers HbA1c and promotes weight loss in patients with Type 2 Diabetes compared to other glucose-lowering therapies.

For patients with Type 2 Diabetes, once-weekly subcutaneous semaglutide at 1.0mg is a highly effective treatment for lowering HbA1c (reducing it by 1.6-1.9%) and promoting weight loss. It is superior to other common glucose-lowering medications and even other GLP-1 RAs like dulaglutide in head-to-head comparisons.

GLP-1 receptor agonists (semaglutide, tirzepatide) produce 15–25% mean weight loss and reduce cardiovascular events by 20% and type 2 diabetes incidence by 72%.

If you have obesity or overweight with a related health condition, GLP-1 medications like semaglutide (Wegovy) or tirzepatide (Zepbound) are currently the most effective pharmacological treatments, offering 15-25% weight loss and significant cardiovascular benefits. These require weekly injections (or oral forms for some) and work best when combined with a modest caloric deficit and regular exercise. Be aware of potential gastrointestinal side effects and the need for long-term management, as stopping the medication often leads to weight regain.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, achieves higher mean weight loss (up to 20.9%) than selective GLP-1 agonists.

Tirzepatide (Zepbound) is a once-weekly injection that targets both GIP and GLP-1 receptors, resulting in an average 20.9% weight loss over 72 weeks, which is higher than semaglutide. It is indicated for adults with obesity or overweight with comorbidities. Like other GLP-1 agonists, it requires lifestyle changes and may cause gastrointestinal side effects. Access may be limited by cost and insurance coverage.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, significantly reduces HbA1c (by 1.7–2.4%) and body weight (up to 22.5%) in patients with type 2 diabetes compared to placebo, semaglutide, and insulin therapies.

Tirzepatide is a once-weekly injection for type 2 diabetes that significantly lowers blood sugar and promotes substantial weight loss. It starts at a low dose (2.5 mg) to minimize stomach issues, then increases every 4 weeks up to 15 mg. It is more effective for weight loss and A1C reduction than insulin or semaglutide in head-to-head trials. Common side effects are gastrointestinal (nausea, diarrhea) but are usually mild. It is contraindicated for those with a history of medullary thyroid carcinoma.

GLP-1 receptor agonists (GLP-1 RAs) produce significant weight loss (7–24%) and HbA1c reductions (1.5–2.0%) through pleiotropic mechanisms including enhanced mitochondrial function, anti-inflammatory actions, and improved cellular quality control.

GLP-1 medications are highly effective for weight loss and blood sugar control. They work through multiple biological pathways, not just hunger suppression. Newer oral versions exist for those who prefer pills over injections. Consult a doctor to determine the right agent and dose for your specific health profile.

GLP-1 receptor agonists (e.g., semaglutide, liraglutide, tirzepatide) reduce major adverse cardiovascular events (MACE) including myocardial infarction, stroke, and cardiovascular mortality in patients with type 2 diabetes and established cardiovascular disease, as well as in non-diabetic patients with obesity and cardiovascular disease.

If you have Type 2 Diabetes and heart disease, or obesity and heart disease, GLP-1 agonists like semaglutide or liraglutide are proven to significantly lower your risk of heart attack, stroke, and heart-related death. This benefit exists alongside blood sugar control. Discuss with your doctor if you are a candidate, considering the cost and injection/oral delivery options.

Contemporary NuSH anti-obesity medications (semaglutide, tirzepatide) produce significantly greater weight loss than intensive lifestyle interventions alone.

If you are struggling to lose weight despite strict diet and exercise, it may be biological, not behavioral. AOMs can produce 15%+ weight loss, far exceeding what lifestyle changes alone typically achieve. Consult a doctor to see if you are a candidate.